Information Provided By:
Fly News Breaks for October 13, 2015
ILMN, PACB
Oct 13, 2015 | 07:27 EDT
Cantor increased its price target on Pacific Biosciences (PACB) after the company launched its new Sequel product, as the firm thinks that the product will enable the company to become more competitive with Illumina (ILMN). Cantor expects Pacific to place 60 Sequels and Roche Dx instruments over the next 12 months. It keeps a Buy rating on the shares.
News For PACB;ILMN From the Last 2 Days
There are no results for your query PACB;ILMN